Clinical Trials Browser

Phase 1/2 × Terminated × ganitumab × Clear all

NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

NCT00791154 2024-08-23

SCLC

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Phase 1/2 Terminated

89 enrolled 20 charts

GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Phase 1/2 Terminated

47 enrolled 23 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms